dbi-001
Small moleculeexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Sep 12, 2019 (NCT04315051)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Glucose transporterINHIBITOR
SLC2A1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05491603 | Phase 2 | Oct 31, 2022 | DermBiont, Inc. |
| NCT05493488 | Phase 2 | Sep 8, 2022 | DermBiont, Inc. |
| NCT05253755 | Phase 2 | Oct 6, 2021 | DermBiont, Inc., Derm Research, PLLC |
| NCT04315051 | Phase 2 | Sep 12, 2019 | DermBiont, Inc., Instituto Dermatologico y Cirugia de Piel |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DermBiont, Inc. | For profit | 4 | 4 | 1 | 2019 |
| Derm Research, PLLC | For profit | 1 | 0 | 1 | 2021 |
| Instituto Dermatologico y Cirugia de Piel | Academic/Hospital | 1 | 0 | 1 | 2019 |
3 organizations
Page 1 / 1